Century Total Current Liabilities vs Total Liab Analysis
| IPSC Stock | USD 1.63 0.28 20.74% |
Century Therapeutics financial indicator trend analysis is way more than just evaluating Century Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Century Therapeutics is a good investment. Please check the relationship between Century Therapeutics Total Current Liabilities and its Total Liab accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.
Total Current Liabilities vs Total Liab
Total Current Liabilities vs Total Liab Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Century Therapeutics Total Current Liabilities account and Total Liab. At this time, the significance of the direction appears to have almost identical trend.
The correlation between Century Therapeutics' Total Current Liabilities and Total Liab is 0.96. Overlapping area represents the amount of variation of Total Current Liabilities that can explain the historical movement of Total Liab in the same time period over historical financial statements of Century Therapeutics, assuming nothing else is changed. The correlation between historical values of Century Therapeutics' Total Current Liabilities and Total Liab is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Current Liabilities of Century Therapeutics are associated (or correlated) with its Total Liab. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Liab has no effect on the direction of Total Current Liabilities i.e., Century Therapeutics' Total Current Liabilities and Total Liab go up and down completely randomly.
Correlation Coefficient | 0.96 |
| Relationship Direction | Positive |
| Relationship Strength | Very Strong |
Total Current Liabilities
Total Current Liabilities is an item on Century Therapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Century Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.Total Liab
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.Most indicators from Century Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Century Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.The current year's Tax Provision is expected to grow to about 2.9 M, whereas Selling General Administrative is forecasted to decline to about 33.3 M.
| 2021 | 2022 | 2023 | 2024 (projected) | Cost Of Revenue | 4.6M | 10.1M | 13.0M | 12.4M | Research Development | 75.6M | 107.2M | 92.7M | 55.0M |
Century Therapeutics fundamental ratios Correlations
Click cells to compare fundamentals
Century Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Century Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Century Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Century Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Century Therapeutics Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Century Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Century Stock refer to our How to Trade Century Stock guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Century Therapeutics. If investors know Century will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Century Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Revenue Per Share 0.037 | Quarterly Revenue Growth 4.345 | Return On Assets (0.21) | Return On Equity (0.63) |
The market value of Century Therapeutics is measured differently than its book value, which is the value of Century that is recorded on the company's balance sheet. Investors also form their own opinion of Century Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Century Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Century Therapeutics' market value can be influenced by many factors that don't directly affect Century Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Century Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Century Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Century Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.